Purpose: The aims of this study were to describe the most common medications reported by candidates for weight loss surgery and to consider the potential implications for patient care. Methods: A secondary data analysis of data from bariatric surgery patients enrolled in a randomized, controlled trial. At study entry, participants recorded their use of prescription medications they had taken in the previous 90 days. The Anatomical Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) Index 2014 was used to classify medications. Results: Participants (n=265) were 85.7% female and 83.0% white. Mean body mass index was 47.9±6.5 kg/m2, and age was 45.1±11 years. The average number of medications was 4.4±4.1, and the median was 3. The top three anatomical main groups were the cardiovascular system, alimentary tract and metabolism, and nervous system (28.2%, 21.6%, and 21.3% of all medications, respectively). The top therapeutic subgroups were drugs used in diabetes, psychoanaleptics, and agents acting on the renin-angiotensin system (12%, 11.3%, and 8.2% of all medications, respectively). Conclusions: Candidates for weight loss surgery report taking medications associated with obesity-related comorbidities such as diabetes, depression, and hypertension. Although many may be able to eliminate these medications, others will require close monitoring and dosage adjustment after surgery.
RCT Entities:
Purpose: The aims of this study were to describe the most common medications reported by candidates for weight loss surgery and to consider the potential implications for patient care. Methods: A secondary data analysis of data from bariatric surgery patients enrolled in a randomized, controlled trial. At study entry, participants recorded their use of prescription medications they had taken in the previous 90 days. The Anatomical Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) Index 2014 was used to classify medications. Results:Participants (n=265) were 85.7% female and 83.0% white. Mean body mass index was 47.9±6.5 kg/m2, and age was 45.1±11 years. The average number of medications was 4.4±4.1, and the median was 3. The top three anatomical main groups were the cardiovascular system, alimentary tract and metabolism, and nervous system (28.2%, 21.6%, and 21.3% of all medications, respectively). The top therapeutic subgroups were drugs used in diabetes, psychoanaleptics, and agents acting on the renin-angiotensin system (12%, 11.3%, and 8.2% of all medications, respectively). Conclusions: Candidates for weight loss surgery report taking medications associated with obesity-related comorbidities such as diabetes, depression, and hypertension. Although many may be able to eliminate these medications, others will require close monitoring and dosage adjustment after surgery.
Authors: James L Roerig; Kristine Steffen; Cheryl Zimmerman; James E Mitchell; Ross D Crosby; Li Cao Journal: Surg Obes Relat Dis Date: 2010-12-15 Impact factor: 4.734
Authors: James E Mitchell; Faith Selzer; Melissa A Kalarchian; Michael J Devlin; Gladys W Strain; Katherine A Elder; Marsha D Marcus; Steve Wonderlich; Nicholas J Christian; Susan Z Yanovski Journal: Surg Obes Relat Dis Date: 2012-07-14 Impact factor: 4.734
Authors: Melinda A Maggard; Lisa R Shugarman; Marika Suttorp; Margaret Maglione; Harvey J Sugerman; Harvey J Sugarman; Edward H Livingston; Ninh T Nguyen; Zhaoping Li; Walter A Mojica; Lara Hilton; Shannon Rhodes; Sally C Morton; Paul G Shekelle Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391
Authors: Martin A Makary; Jeanne M Clark; Jeanne M Clarke; Andrew D Shore; Thomas H Magnuson; Thomas Richards; Eric B Bass; Francesca Dominici; Jonathan P Weiner; Albert W Wu; Jodi B Segal Journal: Arch Surg Date: 2010-08
Authors: B L da S Guedes; M C Montanha; J J V Teixeira; A Diniz; S R B Silva; I Previdelli; D Nasser; S S Yamada; E Kimura Journal: J Clin Pharm Ther Date: 2014-10-10 Impact factor: 2.512
Authors: Elissa A Falconer; DeAngelo A Harris; Amanda Van Prooyen; Jessica Hicks; Arvinpal Singh; S Scott Davis; Edward Lin; Jyotirmay Sharma; Jonathan Pollock; Daniel V Samarov; Elizabeth M Hechenbleikner Journal: Surg Endosc Date: 2021-02-12 Impact factor: 4.584